Aaron Rodgers, David Bakhtiari rip Dianne Feinstein over 'unusual' stock trades [FOX News]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: FOX News
close Aaron Rodgers and his former Green Bay Packers teammate David Bakhtiari called out Sen. Dianne Feinstein, D-Calif., after a thread on Twitter took a look at some of her "unusual" stock trades. Unusual Whales broke down Feinstein's trades over the last decade or so and wrote that it helped her net worth allegedly reach $200 million. Feinstein became a senator in 1992 and before that, she served as the mayor of San Francisco. But Bakhtiari and Rodgers were not happy with what they read from the Unusual Whales report. "How are we as a nation just ‘cool' with actions like this? It's cheating in broad daylight," the three-time Pro Bowler Bakhtiari wrote in a tweet. Rodgers appeared to agree. "Finally Dave, (hashtag) this gif is you," he added on Twitter with a gif of Ryan Reynolds in the movie "Free Guy." Unusual Whales reported the 89-year-old Feinstein or her late husband, Richard Blum, sold millions in Allogene Therapeutics stock before the market took a tumble in 2
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Q2 Investor Conference ParticipationGlobeNewswire
- We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside [Seeking Alpha]Seeking Alpha
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
ALLO
Earnings
- 3/14/24 - Miss
ALLO
Sec Filings
- 3/18/24 - Form 4
- 3/14/24 - Form S-8
- 3/14/24 - Form S-3
- ALLO's page on the SEC website